Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC
Hunan Province Tumor Hospital
Hunan Province Tumor Hospital
Hunan Province Tumor Hospital
The First Affiliated Hospital of Xinxiang Medical College
Samsung Medical Center
Qingdao Central Hospital
Qingdao Central Hospital
National Cancer Institute, Naples
University of Leicester
The Second Affiliated Hospital of Shandong First Medical University
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Cambridge University Hospitals NHS Foundation Trust
Fujian Cancer Hospital
Qianfoshan Hospital
Tianjin Medical University Cancer Institute and Hospital
Fudan University
Sichuan Cancer Hospital and Research Institute
The First Affiliated Hospital of Zhengzhou University
National Cancer Center, Korea
The Netherlands Cancer Institute
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Shanghai Chest Hospital
Guangdong Association of Clinical Trials
Second Affiliated Hospital of Nanchang University
Sichuan Cancer Hospital and Research Institute
Second Affiliated Hospital, School of Medicine, Zhejiang University
Guangdong Association of Clinical Trials
Second Affiliated Hospital of Nanchang University
Sun Yat-sen University
Genor Biopharma Co., Ltd.
Second Affiliated Hospital of Nanchang University
The University of Hong Kong
Sun Yat-sen University
Sinocelltech Ltd.
Peking University Cancer Hospital & Institute
Samsung Medical Center
National Taiwan University Hospital
Luye Pharma Group Ltd.
Beijing Hospital
Qilu Pharmaceutical Co., Ltd.
Grupo de Investigación y Divulgación Oncológica
Tongji University
Karolinska University Hospital
Sun Yat-sen University
Tang-Du Hospital
Zhejiang University
Huazhong University of Science and Technology
Sichuan Cancer Hospital and Research Institute
St. John Providence Health System
The Cooper Health System